Debiopharm is an independent biopharmaceutical company based in Switzerland, dedicated to improving patient outcomes and quality of life, particularly in oncology and bacterial infections. With over 45 years of experience, the company focuses on drug development, drug manufacturing, and investments in digital health. Debiopharm operates through three main entities: Debiopharm International for drug development, Debiopharm Research & Manufacturing for production, and the Debiopharm Innovation Fund for strategic investments in health technology.